杏林製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4569/E00985 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2022/04/08 | 日証協 | 325,715株 | +16.36% | 370,704株 | +65.29% | 386,708株 | -7.83% | 333,101株 | -37.19% |
2022/04/01 | 日証協 | 279,925株 | -16.88% | 224,281株 | -33.98% | 419,557株 | -6.69% | 530,364株 | +74.73% |
2022/03/25 | 日証協 | 336,780株 | -14.06% | 339,698株 | +771.87% | 449,620株 | +9.56% | 303,534株 | +282.62% |
2022/03/18 | 日証協 | 391,874株 | -3.32% | 38,962株 | -24.77% | 410,397株 | +1.18% | 79,331株 | -76.95% |
2022/03/11 | 日証協 | 405,312株 | -15.52% | 51,792株 | -6.69% | 405,616株 | -21.88% | 344,190株 | +12.72% |
2022/03/04 | 日証協 | 479,784株 | -4.01% | 55,504株 | +302.2% | 519,220株 | +1.07% | 305,338株 | +1405.91% |
2022/02/25 | 日証協 | 499,849株 | -8.9% | 13,800株 | -62.09% | 513,726株 | -7.49% | 20,276株 | -82.79% |
2022/02/18 | 日証協 | 548,656株 | -1.08% | 36,406株 | -35.8% | 555,326株 | -3.14% | 117,808株 | -8.67% |
2022/02/10 | 日証協 | 554,630株 | -0.1% | 56,706株 | +0.94% | 573,300株 | -3.22% | 128,997株 | -21.45% |
2022/02/04 | 日証協 | 555,175株 | +1.73% | 56,177株 | -9.03% | 592,358株 | +2.87% | 164,221株 | -9.87% |
2022/01/28 | 日証協 | 545,729株 | +6.07% | 61,754株 | +38.45% | 575,858株 | +1.68% | 182,195株 | -13.85% |
2022/01/21 | 日証協 | 514,508株 | -10.27% | 44,605株 | +253.2% | 566,317株 | -4.76% | 211,498株 | +425.47% |
2022/01/14 | 日証協 | 573,381株 | -16.9% | 12,629株 | -96.71% | 594,651株 | -17.47% | 40,249株 | -65.24% |
2022/01/07 | 日証協 | 689,979株 | +2.42% | 383,956株 | +1.48% | 720,570株 | -0.53% | 115,787株 | -47.45% |
2021/12/30 | 日証協 | 673,698株 | 0% | 378,373株 | 0% | 724,410株 | 0% | 220,340株 | 0% |
2021/12/24 | 日証協 | 673,698株 | +9.65% | 378,373株 | +64.77% | 724,410株 | +9.01% | 220,340株 | +25.67% |
2021/12/17 | 日証協 | 614,407株 | +3.98% | 229,633株 | +30.04% | 664,515株 | +6.9% | 175,335株 | -33.78% |
2021/12/10 | 日証協 | 590,890株 | +9.85% | 176,584株 | +25.03% | 621,623株 | +12.66% | 264,787株 | +110.27% |
2021/12/03 | 日証協 | 537,901株 | +4.34% | 141,233株 | +185.83% | 551,752株 | +9.93% | 125,928株 | +166.93% |
※株式分割は考慮していませんのでご注意ください。
Page Top